School of Medicine Publications and Presentations
Document Type
Article
Publication Date
1-24-2024
Abstract
Poly (ADP [adenosine diphosphate]-ribose) polymerase inhibitors (PARPi) are a current standard of care treatment option for patients with metastatic castration resistant prostate cancer (mCRPC), defined as prostate cancers that continue to progress despite treatment with the usual first-line androgen-deprivation therapies. PARPi’s function by targeting faulty homologous recombination repair pathways that result in cytotoxic double strand DNA break (DSB) accumulation in prostate cancer cells. While the efficacy of PARPi’s as a monotherapy option in mCRCP has been demonstrated clinically, the added utility of PARPi’s in combination with other anti-cancer agents is still being explored. This article will review the scientific rationale behind PARP-inhibitors, discuss the germline and somatic mutation testing critical to identifying predictive biomarkers for PARPi efficacy, and present the currently approved PARPi combination therapies and their indications. This review will also examine the incidence and management of PARPi toxicity, summarize ongoing trials, and propose areas of future study.
Recommended Citation
Tawagi, K., Schmolze, M., Nguyen, B., Laviana, A., & Reizine, N. (2024). PARP Inhibitors in Prostate Cancer–Understanding the Current Landscape. International Journal of Cancer Care and Delivery. https://doi.org/10.53876/001c.92258
Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 4.0 International License.
Publication Title
International Journal of Cancer Care and Delivery
DOI
10.53876/001c.92258
Academic Level
medical student
Comments
This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CCBY-SA-4.0). View this license’s legal deed at https://creativecommons.org/licenses/by-sa/4.0 and legal code at https://creativecommons.org/licenses/by-sa/4.0/legalcode for more information.